4//SEC Filing
Nexvet Biopharma plc 4
Accession 0001572426-16-000194
CIK 0001618561operating
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 8:20 PM ET
Size
11.9 KB
Accession
0001572426-16-000194
Insider Transaction Report
Form 4
Heffernan Mark
Chief Executive Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2016-07-01$0.13/sh+4,833$604→ 24,167 total - Exercise/Conversion
Restricted Share Units
2016-07-01−25,000→ 75,000 totalExercise: $0.13Exp: 2020-07-01→ Ordinary Shares (25,000 underlying) - Exercise/Conversion
Ordinary Shares
2016-07-01$0.13/sh+25,000$3,125→ 49,167 total - Exercise/Conversion
Option to Purchase Shares
2016-07-01−4,833→ 4,833 totalExercise: $0.13Exp: 2019-07-01→ Ordinary Shares (4,833 underlying)
Holdings
- 243,587(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
Ordinary Shares
Footnotes (4)
- [F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
- [F2]The remaining 4,833 options to purchase shares will vest and become exercisable on 7/1/17.
- [F3]Previously reported as indirectly held.
- [F4]25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/17, 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
Documents
Issuer
Nexvet Biopharma plc
CIK 0001618561
Entity typeoperating
IncorporatedIreland
Related Parties
1- filerCIK 0001618561
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 8:20 PM ET
- Size
- 11.9 KB